Analysts expect Aligos Therapeutics, Inc. to report revenue of 574,555.25 for Q4 26, against a range of 549,737.34 to 599,373.16. The most recent reported quarter, Q3 26, came in at 2.87 M, a 37.5% miss against the 4.59 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 629,000.00 | 311,000.00 | 965,000.00 | 741,000.00 | 169,000.00 | 2.83 M | 27.78 M | 2.87 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 458,257.65 | 502,780.09 | 425,239.68 | 486,599.69 | 463,376.39 | 252,262.03 | 27.09 M | 4.79 M | 599,373.16 | 230,530.99 | 246,434.36 | 240,756.38 | 276,255.17 | 915,844.96 | 2.03 M | 1.05 M | |||||||||
| Low Estimate | 387,199.51 | 472,934.91 | 396,887.00 | 455,105.31 | 388,987.21 | 236,935.47 | 24.40 M | 4.39 M | 549,737.34 | 198,779.21 | 215,209.24 | 206,029.50 | 242,595.27 | 834,574.72 | 1.71 M | 928,529.47 | |||||||||
| Consensus Estimate | 422,728.58 | 487,857.50 | 411,063.34 | 470,852.50 | 426,181.80 | 244,598.75 | 25.74 M | 4.59 M | 574,555.25 | 214,655.10 | 230,821.80 | 223,392.94 | 259,425.22 | 875,209.84 | 1.87 M | 987,034.98 |
Analysts expect Aligos Therapeutics, Inc. to report earnings per share of -1.98 for Q4 26, against a range of -2.15 to -1.81. The most recent reported quarter, Q3 26, came in at -2.09, a 12.6% beat against the -2.39 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -13.08 | -2.11 | -1.53 | -3.04 | -1.91 | -2.21 | -0.14 | -2.09 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -2.19 | -2.94 | -2.13 | -1.66 | -2.37 | -2.18 | -1.00 | -2.18 | -1.81 | -1.70 | -1.60 | -1.17 | -0.23 | -0.77 | -1.49 | -2.40 | |||||||||
| Low Estimate | -2.55 | -3.16 | -2.27 | -1.90 | -2.73 | -2.42 | -1.12 | -2.60 | -2.15 | -1.94 | -1.74 | -1.35 | -0.27 | -0.85 | -1.69 | -2.68 | |||||||||
| Consensus Estimate | -2.37 | -3.05 | -2.20 | -1.78 | -2.55 | -2.30 | -1.06 | -2.39 | -1.98 | -1.82 | -1.67 | -1.26 | -0.25 | -0.81 | -1.59 | -2.54 |
Pull Wall Street consensus for Aligos Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ALGS&mode=revenue&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ALGS", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/estimates?ticker=ALGS&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();